Table 2.

Patient demographics and disease characteristics at baseline

CharacteristicTotal study population (N = 79)
Sex, n, %
 Male45 (57.0)
 Female34 (43.0)
Median age, y (range)61.2 (16.8–86.7)
Race/ethnicity, n, %
 White65 (82.3)
 Black5 (6.3)
 Asian4 (5.1)
 Hispanic4 (5.1)
 Other1 (1.3)
Median time since cancer diagnosis, y (range)3.6 (0.2–32.7)
Cancer stage at entry, n, %
 I0 (0)
 II5 (6.3)
 III16 (20.3)
 IV56 (70.9)
 Unknown2 (2.5)
Cancer type, n, %
 Colon/rectum11 (13.9)
 Renal10 (12.6)
 Ovarian6 (7.6)
 Pancreas6 (7.6)
 Sarcoma6 (7.6)
 Thyroid4 (5.1)
 NSCLC4 (5.1)
 Urothelial tract/bladder4 (5.1)
 Prostate3 (3.8)
 Breast2 (2.5)
 Nasopharyngeal2 (2.5)
 Neuroendocrine2 (2.5)
 Head and Neck2 (2.5)
 Other17 (21.5)
Karnofsky performance status, n (%)
 10010 (12.7)
 9037 (46.8)
 8032 (40.5)
Median number of prior anticancer therapies (range)9 (2–33)
Median number of prior anticancer systemic regimens3 (0–12)